Quintiles looks to biomarkers to speed up cancer trials

Quintiles ($Q), the world's largest CRO, has launched a study to determine whether preprofiling cancer patients for key biomarkers can ease trial enrollment and speed drug development. Through the study, researchers will conduct genomic profiling on metastatic colorectal cancer patients up front, screening for biomarkers targeted by both approved and in-development drugs, and then using that information to put patients in the right clinical trials. Article | Release